Imugene Ltd · ASX:IMU
Imugene — Azer-cel Webinar September 2024
14 slides from Imugene's conference presentation, September 2024
Slide 1: Leading Innovation in Cancer Treatment
ASX:IMU Leading Innovation in Cancer Treatment September 2024 Release authorised by the Managing Director and Chief Executive Officer, Imugene Limited.
Slide 2: Disclaimer
Disclaimer The information in this presentation does not constitute personal Neither the Company nor any of its directors, officers, employees, investment advice. The presentation is not intended to be comprehensive advisers, associated persons or subsidiaries are liable for any direct, or provide a
Slide 3: Imugene is a clinical stage cancer company developing three drug products
Imugene is a clinical stage cancer company developing three drug products in CAR T cell therapy and oncolytic viruses. 3
Slide 4: Investment Highlights
Investment Highlights Market Capitalisation A$500M Cash Position A$93.1M (Pro-forma) As of 2 September 2024 As of 30 June2024 4 PLATFORM DISEASE AREAS LONG- TECHNOLOGIES Blood cancers LIFE Breast (TNBC) Lung (NSCLC) PATENT Gastric PORTFOLIO Gastroesophageal Colorectal (CRC) Melanoma 4 Head and Neck
Slide 5: Azer-cel CD19 CAR T for Blood Cancer
AZER-CEL CD19 CAR T FOR BLOOD CANCER 5 5
Slide 6: 67% CR Rates Observed in Phase 1b Cohort B
67% CR Rates Observed in Phase 1b Cohort B Evaluable patients: Evaluable Evaluable Cohort A+B patients: patients: (N=9) Cohort A (N=6) Cohort B (N=3)* Cohort A Overall 6 Response Rate % 4 (44%) 2 (33%) 2 (67%) Patients Complete 3 (33%) 1 (17%) 2 (67%) Lymphodepletion (LD)1 Response % +azer-cel Best
Slide 7: Azer-cel has a Manageable Safety Profile
Azer-cel has a Manageable Safety Profile No evidence of GVHD or GR. >3 CRS CRS ICANS Infections Safety Profile • Manageable CRS occurs within first week but resolves quickly • In Cohort B, no ICANS has been observed to date • While infections have Cohort A Cohort B azer-cel azer-cel + IL-2 occurred,
Slide 8: Addition of IL-2 to Dosing Regimen Enhances CAR-T Expansion and Possibly Efficacy In Vivo
Addition of IL-2 to Dosing Regimen Enhances CAR-T Expansion and Possibly Efficacy In Vivo IL-2 effect on azer-cel persistence Cohort A Median, DL4b/AugCy (no IL-2) n=12 Cohort B Median, DL4b/AugCy (plus IL-2) n=4 • Limited expansion seen in vivo in the absence of IL-2 • Higher C-Max in patients with
Slide 9: Representative PET Scans of Complete Responses
Representative PET Scans of Complete Responses Subject Treatment Summary • 60 yo female, first diagnosed with DLBCL, stage IV Tumour Tumour-free in Apr 2012. Treated at University of Minnesota (UMN). • Prior to azer-cel, patient failed 5 prior lines of therapy; R-CHOP x 6; Rituxan, RICE x 2 followed
Slide 10: Azer-cel Clinical Development Strategy
Azer-cel Clinical Development Strategy Phase 1 Open label Seek FDA Randomised completed clearance 1 2023 2 Phase 1b trial ongoing 3 for Phase 2 4 Phase 2/3 registration n=84 registration n=10-20 trial trial 2020-2023 2024-2025 2025 2025-2026 Milestones: • Preliminary early DLBCL Phase 1b data update
Slide 11: Experienced Leadership Team has brought >17 FDA Approved Drugs to Market
Experienced Leadership Team has brought > 17 FDA Approved Drugs to Market Leslie Chong Dr. Paul Woodard, MD Dr Bradley Glover, PhD Ursula McCurry Dr. John Byon, MD, PhD Dr Monil Shah Chief Executive Officer Chief Medical Officer MBA Chief Clinical Senior VP of Clinical Head of Business & Managing Di
Slide 12: Expected Upcoming Key Catalysts
Expected Upcoming Key Catalysts H2 2024 2025-Beyond • azer-cel: Preliminary early DLBCL • azer-cel: DLBCL Phase 1b interim data update Phase 1b data update • azer-cel: Target regulatory meeting with FDA • onCARlytics: FPI IT Combo Cohort 1 • azer-cel: FPI in registration Phase 2/3 study • onCARlytic
Slide 13: Investment Highlights
Investment Highlights Robust platform technologies supporting 4 clinical trials with >200 patients treated to date in US and Australia, all under FDA INDs Novel platforms in Strong cash Clinical data Deeply Robust and immuno- position of $93 readouts over experienced broad patent oncology, cell mill
Slide 14: ASX: IMU shareholderenquiries@imugene.com imugene.com
ASX : IMU shareholderenquiries@imugene.com imugene.com 14